Table 2.

Occurrence of severe adverse events of interest.

Severe adverse events of interest	Probable-LAM	TSC-LAM
N	208	33
Cytopenia requiring hospitalization:	10 (4.8%)	2 (6.1%)
Anemia	8 (3.9%)	1 (3.0%)
Neutropenia	2 (1.0%)	1 (3.0%)
Thrombocytopenia	0	0
Pneumonia requiring hospitalizations	16 (7.7%)	1 (3.0%)
Opportunistic infections requiring hospitalization	10 (4.8%)	2 (6.1%)
Initiation of lipid lowering therapies within 6 M after sirolimus initiation	7 (3.4%)	2 (6.1%)
Lymphomas or skin cancers	3 (1.4%)	0
Respiratory tract hemorrhage requiring hospitalization	1 (0.5%)	0
High blood pressure flare-ups requiring hospitalization	1 (0.5%)	1 (3.0%)
Hospitalization for hypercholesterolemia after sirolimus initiation	1 (0.5%)	0
Hospitalization for hypercholesterolemia within 1 year after sirolimus initiation	1 (0.5%)	0
Multifocal leukoencephalopathies requiring hospitalization	0	0
Drug-induced interstitial lung disorders	0	0